<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-712" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Quinapril</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tandan</surname>
            <given-names>Nitin</given-names>
          </name>
          <aff>Southern Illinois University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassagnol</surname>
            <given-names>Manouchkathe</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nitin Tandan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-712.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Quinapril is an angiotensin-converting enzyme inhibitor (ACEi) developed in the 1980s. Quinapril is a medication utilized to manage hypertension, a significant risk factor for coronary heart disease. In addition, quinapril is used off-labeled for managing chronic heart failure (CHF), slowing the progression of renal disease in patients with diabetes. Quinapril is a non-sulfhydryl ACEi that blocks the action of angiotensin-converting enzyme (ACE), which plays a vital role in the renin-angiotensin-aldosterone system (RAAS).&#x000a0;Quinapril has effectively lowered systolic blood pressure by 13 mm Hg and diastolic blood pressure by 10 mm Hg in approximately&#x000a0;2 out of&#x000a0;3 individuals. As is true for most drugs in this class, the medication regimen may be increased or decreased depending on patient response.</p>
        <p>This activity reviews the indications, mechanism of action, administration, adverse events, contraindications, monitoring, and toxicity of quinapril. In addition, this article highlights pertinent points regarding quinapril as needed by interprofessional teams managing patients with hypertension and other cardiovascular co-morbidities.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the FDA and non-FDA-approved indications for quinapril therapy based on the patient's cardiovascular condition and risk factors.</p></list-item><list-item><p>Screen patients for contraindications or potential drug interactions before initiating quinapril therapy.</p></list-item><list-item><p>Apply knowledge of quinapril's adverse effects and potential complications to monitor patients for any signs of drug-related adverse events.</p></list-item><list-item><p>Collaborate with other healthcare professionals, such as cardiologists and pharmacists, to optimize the use of quinapril to manage hypertension and cardiovascular conditions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=712&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=712">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-712.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Quinapril is an angiotensin-converting enzyme (ACE) inhibitor developed in the 1980s. Researchers&#x000a0;determined that quinapril had a lower incidence of adverse events than other ACE inhibitors (ACEi) like captopril and enalapril, as well as the thiazide diuretic chlorthalidone.<xref ref-type="bibr" rid="article-712.r1">[1]</xref>&#x000a0;Quinapril has effectively lowered systolic blood pressure by 13 mm Hg and diastolic blood pressure by 10 mm Hg in approximately&#x000a0;2 out of&#x000a0;3 individuals.<xref ref-type="bibr" rid="article-712.r2">[2]</xref><xref ref-type="bibr" rid="article-712.r3">[3]</xref><xref ref-type="bibr" rid="article-712.r4">[4]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The FDA approved quinapril for the treatment of hypertension in 1989.<xref ref-type="bibr" rid="article-712.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Quinapril is indicated in&#x000a0;managing heart failure as an adjunctive therapy when added to&#x000a0;conventional treatment,&#x000a0;which can include diuretics and/or digitalis.<xref ref-type="bibr" rid="article-712.r5">[5]</xref>&#x000a0;According to 2022 AHA/ACC/HFSA guidelines, quinapril is suggested for&#x000a0;heart failure with reduced ejection fraction&#x000a0;(HFrEF). ACEi are the cornerstone&#x000a0;of goal-directed medical therapy (GDMT).<xref ref-type="bibr" rid="article-712.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>As a class, ACEi&#x000a0;has reduced proteinuria in diabetic patients. More importantly, research has demonstrated that quinapril reduces microalbuminuria in essential hypertension and diabetic patients without significantly affecting insulin effectiveness or lipid levels.<xref ref-type="bibr" rid="article-712.r7">[7]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-712.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Quinapril is a non-sulfhydryl ACEi that blocks the action of ACE, which plays a vital role in the renin-angiotensin-aldosterone system (RAAS). Quinapril is metabolized to quinaprilat in the liver, where the drug enters circulation. After conversion, the liver releases quinaprilat into the peripheral circulation, inhibiting ACE; the enzyme converts angiotensin I to angiotensin II. Angiotensin II is the hormone that stimulates the hormone aldosterone, which is responsible for salt and water retention.<xref ref-type="bibr" rid="article-712.r8">[8]</xref>&#x000a0;</p>
        <p>A combination of salt and water retention and peripheral vasculature constriction leads to systemic hypertension. Quinapril (and its metabolite quinaprilat) decreases systemic (peripheral and renal) vascular resistance, thereby decreasing blood pressure. The renal system clears the majority of quinapril,&#x000a0;and ACEi maximum observable effect occurs at 5 hours.<xref ref-type="bibr" rid="article-712.r4">[4]</xref><xref ref-type="bibr" rid="article-712.r9">[9]</xref>&#x000a0;The results of a&#x000a0;study demonstrated that long-term treatment with&#x000a0;quinapril improves impaired endothelial dysfunction in patients with atherosclerotic risk factors.<xref ref-type="bibr" rid="article-712.r10">[10]</xref>&#x000a0;In addition, quinapril improves coronary microvascular dysfunction and coronary flow reserve.<xref ref-type="bibr" rid="article-712.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> The time for peak plasma concentration is within 1 hour. The extent of absorption is approximately 60% (based on&#x000a0;quinapril and its metabolites).</p>
        <p><bold>Distribution:</bold> Quinalapril has plasma protein binding of 97%. Distribution is widespread, except for brain tissue.<xref ref-type="bibr" rid="article-712.r12">[12]</xref></p>
        <p><bold>Metabolism:</bold> Quinapril is converted to its active metabolite quinaprilat. Quinaprilat&#x000a0;has a short elimination half-life but dissociates&#x000a0;from ACE slowly, allowing once or twice daily administration.</p>
        <p><bold>Excretion:</bold> Quinapril and its metabolites are excreted by the kidney.<xref ref-type="bibr" rid="article-712.r13">[13]</xref></p>
      </sec>
      <sec id="article-712.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Quinapril is administered via the oral route.&#x000a0;The drug is available in 5, 10, 20, and 40 mg tablets&#x02014;plasma clearance of quinapril correlates to a patient's creatinine clearance. The dosing range that researchers tested was between 0.625 to 80 mg orally daily, but the most effective antihypertensive effects were noted at doses of 20 mg orally daily.<xref ref-type="bibr" rid="article-712.r3">[3]</xref>&#x000a0;Quinapril is also available&#x000a0;in fixed-dose combination&#x000a0;with&#x000a0;hydrochlorothiazide for the management of hypertension.</p>
        <p>Hypertension: Dosage 10 to 80 mg by mouth daily.&#x000a0;Patients with mild to moderate hypertension should be initiated on a dosage between 5&#x000a0;and 20 mg orally daily, with a dose&#x000a0;increase every 2 weeks, if needed. The dosage should be reduced to 2.5 to 20 mg orally daily in patients with renal impairment.<xref ref-type="bibr" rid="article-712.r14">[14]</xref>&#x000a0;Interestingly, twice daily dosing&#x000a0;achieves a more significant blood pressure trough effect in hypertensive patients than an equivalent total daily dose. Quinapril and hydrochlorothiazide is administered as 20 mg/12.5 mg fixed dose combination.</p>
        <p>Chronic Heart Failure With Reduced Ejection Fraction (HFrEF): Patients with&#x000a0;HFrEF are started on a lower dosage of 5 mg twice daily.&#x000a0;According to the 2022 AHA/ACC/HFSA heart failure guideline, the&#x000a0;target dosage is&#x000a0;20 mg twice daily. The&#x000a0;undesirable adverse effects precipitate (hypotension, orthostasis, or azotemia) may require dose reduction.<xref ref-type="bibr" rid="article-712.r15">[15]</xref></p>
        <p>
<bold>Specific Patient Population&#x000a0;</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;The manufacturer&#x000a0;package insert has no dose adjustment guidance for patients with hepatic impairment.&#x000a0;</p>
        <p><bold>Renal impairment:</bold> The apparent elimination half-life of quinaprilat, the active metabolite of quinapril, increases as creatinine clearance (CrCl) decreases. Therefore, the dose should be adjusted based on&#x000a0;creatinine clearance. Recommended maximum initial doses are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>10 mg if&#x000a0;creatinine&#x000a0;clearance is more than 60 mL/min</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>5 mg if&#x000a0;creatinine&#x000a0;clearance is 30&#x000a0;to 60 mL/min</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>2.5 mg if creatinine clearance is 10&#x000a0;to 30 mL/min</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>No sufficient dose recommendation data is available when&#x000a0;creatinine&#x000a0;clearance is below&#x000a0;10 mL/min.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For hemodialysis or peritoneal dialysis patients, start quinapril at 2.5 mg daily; no supplement is necessary following dialysis.</p>
          </list-item>
        </list>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Quinapril is considered a former FDA pregnancy category&#x000a0;D medicine. Per the manufacturer box warning, discontinuation of quinapril is recommended as soon as pregnancy is detected. Quinapril can cross the placenta, and exposure to ACEi during the first trimester may increase the risk of fetal malformations.<xref ref-type="bibr" rid="article-712.r16">[16]</xref>&#x000a0;According to ACOG, ACEi, including quinapril, is contraindicated in pregnancy as it increases the risk of malformations like renal dysgenesis and fetal growth restriction.<xref ref-type="bibr" rid="article-712.r17">[17]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;The manufacturer&#x000a0;advises caution&#x000a0;for&#x000a0;quinapril therapy in nursing mothers as the drug is present in breast milk.<xref ref-type="bibr" rid="article-712.r18">[18]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Limited data is available for&#x000a0;using quinapril&#x000a0;in pediatric patients, although it can be used off-label for hypertension in children aged 6 and older.&#x000a0;</p>
        <p><bold>Older patients:</bold>&#x000a0;The manufacturer recommends a 10 mg daily dosage followed by titration as the&#x000a0;initial dosage of quinapril in&#x000a0;older patients.</p>
      </sec>
      <sec id="article-712.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of quinapril include dry cough (as&#x000a0;is typical&#x000a0;among all ACEi class members), hyperkalemia, angioedema, dizziness, hypotension, and renal dysfunction.<xref ref-type="bibr" rid="article-712.r19">[19]</xref><xref ref-type="bibr" rid="article-712.r20">[20]</xref><xref ref-type="bibr" rid="article-712.r21">[21]</xref>&#x000a0;Less common adverse effects include skin rash and dysgeusia.<xref ref-type="bibr" rid="article-712.r21">[21]</xref>&#x000a0;Angioedema is a rare but well-documented adverse effect of ACEi, which often presents as facial, tongue, and lip swelling. However, unique instances present with isolated swelling of the small bowel. This presentation, also called intestinal-type angioedema, may manifest in patients taking ACEi presenting with abdominal pain, nausea, vomiting, and diarrhea.<xref ref-type="bibr" rid="article-712.r22">[22]</xref>&#x000a0;Although one report of agranulocytosis is available in a neutropenic patient using quinapril, no other reports of agranulocytosis were noted in the literature, as found in rare cases of captopril use, one of the original ACE inhibitors.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diuretic agents:&#x000a0;Coadministration of quinapril with other diuretics may occasionally reduce&#x000a0;blood pressure after initiating&#x000a0;therapy. To minimize the hypotensive effects, either discontinue the diuretic or cautiously increase the salt intake before starting quinapril therapy. The reduced initial dose of quinapril may be used for patients where discontinuing the diuretic is not feasible.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Agents increasing serum potassium:&#x000a0;Coadministration of quinapril with other&#x000a0;agents that raise&#x000a0;the level of serum potassium may&#x000a0;lead to hyperkalemia. Therefore, monitoring the serum potassium level in such patients is recommended.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tetracycline and other&#x000a0;agents that interact with magnesium:&#x000a0;Coadministration of quinapril with tetracycline&#x000a0;may reduce tetracycline absorption by 28% to 37% due to the high magnesium content in quinapril tablets.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lithium:&#x000a0;Coadministration of quinapril with lithium may increase serum lithium levels, leading to lithium toxicity symptoms.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gold: Coadministration of quinapril with injectable gold may lead to nitritoid reactions, which lead to symptoms&#x000a0;like facial flushing, nausea, vomiting, and hypotension.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Non-steroidal anti-inflammatory agents, including selective cyclooxygenase-2 inhibitors:&#x000a0;Coadministration of quinapril with NSAIDs or selective COX-2 inhibitors in&#x000a0;older patients may result in deterioration of renal function or acute renal failure.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Agents that inhibit mTOR:&#x000a0;Coadministration of quinapril with an mTOR inhibitor (eg, temsirolimus) may&#x000a0;increase the risk for angioedema.</p>
          </list-item>
        </list>
        <p>FDA Safety Alert: In December 2022, quinapril (4 batches)&#x000a0;was withdrawn from the market in a voluntary nationwide recall due to nitrosamine impurity. Nitrosamine is a potential carcinogen; in consequence,&#x000a0;clinicians should&#x000a0;remain&#x000a0;cautious while prescribing.<xref ref-type="bibr" rid="article-712.r23">[23]</xref></p>
      </sec>
      <sec id="article-712.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>ACE inhibitors (ACEi), including quinapril, are contraindicated in pregnancy&#x000a0;since they counteract RAAS, which is essential for fetal renal development.<xref ref-type="bibr" rid="article-712.r21">[21]</xref>&#x000a0;Possible complications of using quinapril in pregnancy may include but are not limited to fetal lung hypoplasia, fetal renal hypoplasia/failure, oligohydramnios, skeletal hypoplasia, hypotension, and death. Quinapril is also contraindicated in patients with hyperkalemia, current angioedema (regardless of the ACEi), bilateral renal artery stenosis, acute kidney injury leading to renal failure with prior ACEi use, and aliskiren use within the last 36 hours. The use of quinapril is contraindicated in patients taking&#x000a0;neprilysin inhibitors (ARNI) such as sacubitril due to the increased risk of angioedema. A period of 36 hours is recommended before switching to or from sacubitril/valsartan and quinapril.<xref ref-type="bibr" rid="article-712.r24">[24]</xref></p>
      </sec>
      <sec id="article-712.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Following the initial dose of quinapril, the patient should be kept&#x000a0;under medical observation for at least&#x000a0;2 hours for hypotension or orthostasis. If present, they should remain under observation until blood pressure normalizes. For each dose increase, similar medical care should be provided to patients to avoid the risk of adverse effects.<xref ref-type="bibr" rid="article-712.r22">[22]</xref>&#x000a0;The most serious adverse effects requiring monitoring are angioedema and hyperkalemia. Clinicians need to inform patients about potential facial, tongue, and lip swelling so that they can monitor for angioedema. Patients and&#x000a0;clinicians must also be cognizant of abdominal symptoms like abdominal pain, nausea, vomiting, and diarrhea, which may suggest intestinal-type angioedema.<xref ref-type="bibr" rid="article-712.r22">[22]</xref>&#x000a0;</p>
        <p>Routine laboratory assessment should be performed, including a basic metabolic panel to monitor serum potassium levels and renal function. The current recommendation is to monitor serum electrolytes and renal function 2&#x000a0;to 3 weeks after initiation and at every dose titration. In addition, patients&#x000a0;should receive instruction to avoid high-potassium foods (ie, alternative salt in hypertension, bananas, avocados) and be advised against concurrent use of other agents that contribute to hyperkalemia (ie, aldosterone antagonists). Patients who take many antihypertensive agents also need to be cautious, as quinapril may contribute to significant hypotension, especially following the administration of the first dose.&#x000a0;</p>
        <p>Occasional or rare monitoring of liver function tests and complete blood counts may be warranted in quinapril as rare adverse effects such as agranulocytosis and hepatic enzyme elevation may occur.<xref ref-type="bibr" rid="article-712.r19">[19]</xref>&#x000a0;If patients report a persistent, dry cough while taking quinapril, the clinician may consider a therapeutic switch to an angiotensin receptor-blocking agent (ARB). According to Primary Prevention of Cardiovascular Disease guidelines by ACC/AHA, the atherosclerotic cardiovascular disease (ASCVD) risk estimator plus should be used to guide treatment decisions. For patients with hypertension, comprehensive lifestyle interventions are suggested. The goal blood pressure is &#x0003c;130/80mm Hg.<xref ref-type="bibr" rid="article-712.r25">[25]</xref>&#x000a0;Volume status, weight, and vitals should be monitored each visit for patients with heart failure on quinapril therapy.&#x000a0;Hemodynamic status should be&#x000a0;monitored&#x000a0;during acute decompensation by&#x000a0;assessment of&#x000a0;perfusion and congestion.&#x000a0; Assessment of patient-reported health status using a standardized questionnaire like the Kansas City Cardiomyopathy Questionnaire (KCCQ) or the Minnesota Living with Heart Failure questionnaire&#x000a0;is&#x000a0;useful as it provides information&#x000a0;regarding&#x000a0;the patient's overall functional status and quality of life.<xref ref-type="bibr" rid="article-712.r6">[6]</xref><xref ref-type="bibr" rid="article-712.r26">[26]</xref></p>
      </sec>
      <sec id="article-712.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Overdosing ACEi may lead to significant hypotension, renal failure, hyperkalemia, and hyponatremia.<xref ref-type="bibr" rid="article-712.r19">[19]</xref><xref ref-type="bibr" rid="article-712.r20">[20]</xref><xref ref-type="bibr" rid="article-712.r21">[21]</xref>&#x000a0;After ingesting 20 times the daily amount, significant hypotension occurred within the first 6 hours of ingestion. Clinicians could&#x000a0;consider activated charcoal if a patient presents within an hour of ingestion.<xref ref-type="bibr" rid="article-712.r27">[27]</xref>&#x000a0;To date, no true antidote for quinapril is available.</p>
        <p>Per the manufacturer, hemodialysis and peritoneal dialysis&#x000a0;may only significantly eliminate quinapril and its metabolite. Angiotensin II can be used&#x000a0;as a specific antidote in&#x000a0;instances of a quinapril overdose. However,&#x000a0;angiotensin II is&#x000a0;only available in research facilities.&#x000a0;Since quinapril causes hypotension through vasodilation and effective hypovolemia, the infusion of the normal saline solution may be helpful when treating quinapril overdose. Insertion of the central line and administration of norepinephrine may be required in refractory hypotension.<xref ref-type="bibr" rid="article-712.r28">[28]</xref></p>
      </sec>
      <sec id="article-712.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Since quinapril&#x000a0;joined the market, it has been an effective medication for treating hypertension and chronic heart failure. Key points to remember are that 1) average systolic blood pressure change is approximately 13 mm Hg while average diastolic blood pressure change is approximately 10 mm Hg with maximum effect at 5 hours, and 2) patients require close monitoring for adverse effects such as hyperkalemia, renal dysfunction, and angioedema.</p>
        <p>Clinicians should determine the dose of quinapril based on the patient's clinical diagnosis and other medical conditions. Nursing staff must monitor vitals, verify the dose before administering the drug, and&#x000a0;consult with the prescriber about their concerns and recommendations. Pharmacists must perform medication reconciliation and counsel patients on the safe use of the drug. During hypertensive urgency and emergency, clinicians should rapidly stabilize the patient. Medical toxicologist consultation may be required in complex overdose. If the overdose is intentional, a psychiatrist consultation is necessary. All interprofessional healthcare team members must communicate openly with each other to ensure optimal patient treatment and outcomes. Prescribing, administering, and monitoring quinapril requires the coordinated effort of an interprofessional healthcare team. According to AHA/ACC/HFSA 2022 guidelines, multiple&#x000a0;clinical trials have shown that patient care provided by an interprofessional team improves outcomes related to hypertension and heart failure therapy.<xref ref-type="bibr" rid="article-712.r6">[6]</xref></p>
      </sec>
      <sec id="article-712.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=712&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=712">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/712/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=712">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-712.s11">
        <title>References</title>
        <ref id="article-712.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frank</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>McLain</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Overall tolerance and safety of quinapril in clinical trials.</article-title>
            <source>Angiology</source>
            <year>1989</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4 Pt 2</issue>
            <fpage>405</fpage>
            <page-range>405-15</page-range>
            <pub-id pub-id-type="pmid">2650583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sedman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Posvar</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.</article-title>
            <source>Angiology</source>
            <year>1989</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4 Pt 2</issue>
            <fpage>360</fpage>
            <page-range>360-9</page-range>
            <pub-id pub-id-type="pmid">2539762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maclean</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Quinapril: a double-blind, placebo-controlled trial in essential hypertension.</article-title>
            <source>Angiology</source>
            <year>1989</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4 Pt 2</issue>
            <fpage>370</fpage>
            <page-range>370-81</page-range>
            <pub-id pub-id-type="pmid">2650581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Begg</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Lynn</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1990</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>213</fpage>
            <page-range>213-20</page-range>
            <pub-id pub-id-type="pmid">2144994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <article-title>Drugs for chronic heart failure.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2021</year>
            <month>Jun</month>
            <day>14</day>
            <volume>63</volume>
            <issue>1626</issue>
            <fpage>89</fpage>
            <page-range>89-96</page-range>
            <pub-id pub-id-type="pmid">34181628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>79</volume>
            <issue>17</issue>
            <fpage>e263</fpage>
            <page-range>e263-e421</page-range>
            <pub-id pub-id-type="pmid">35379503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dominguez</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Barbagallo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kattah</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sowers</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects.</article-title>
            <source>Am J Hypertens</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>808</fpage>
            <page-range>808-14</page-range>
            <pub-id pub-id-type="pmid">7576397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raia</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Barone</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Byerly</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Lacy</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitors: a comparative review.</article-title>
            <source>DICP</source>
            <year>1990</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>506</fpage>
            <page-range>506-25</page-range>
            <pub-id pub-id-type="pmid">2188439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Squire</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Macfadyen</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Hillis</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-23</page-range>
            <pub-id pub-id-type="pmid">7981011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Elstein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haber</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Charbonneau</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study).</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-6</page-range>
            <pub-id pub-id-type="pmid">10636260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marinescu</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>L&#x000f6;ffler</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Ouellette</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bourque</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Coronary microvascular dysfunction, microvascular&#x000a0;angina, and treatment strategies.</article-title>
            <source>JACC Cardiovasc Imaging</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>210</fpage>
            <page-range>210-20</page-range>
            <pub-id pub-id-type="pmid">25677893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Quinapril--a preclinical review of the pharmacology, pharmacokinetics, and toxicology.</article-title>
            <source>Angiology</source>
            <year>1989</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4 Pt 2</issue>
            <fpage>335</fpage>
            <page-range>335-50</page-range>
            <pub-id pub-id-type="pmid">2539761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kieback</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Felix</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Reffelmann</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>10</issue>
            <fpage>1337</fpage>
            <page-range>1337-47</page-range>
            <pub-id pub-id-type="pmid">19761414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Texter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gmerek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shurzinske</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Canter</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Quinapril hydrochloride effects on renal function in patients with renal dysfunction and hypertension: a drug-withdrawal study.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>1994</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>271</fpage>
            <page-range>271-5</page-range>
            <pub-id pub-id-type="pmid">7918140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>79</volume>
            <issue>17</issue>
            <fpage>1757</fpage>
            <page-range>1757-1780</page-range>
            <pub-id pub-id-type="pmid">35379504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarween</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lipkin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>221</fpage>
            <page-range>221-31</page-range>
            <pub-id pub-id-type="pmid">25612630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>e26</fpage>
            <page-range>e26-e50</page-range>
            <pub-id pub-id-type="pmid">30575676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Quinapril</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>2</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">30000147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Quinapril</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>2</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">31643770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Canter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>McLain</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The safety profile of quinapril: is there a difference among ACE inhibitors?</article-title>
            <source>Clin Cardiol</source>
            <year>1990</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6 Suppl 7</issue>
            <fpage>VII39</fpage>
            <page-range>VII39-42</page-range>
            <pub-id pub-id-type="pmid">2189620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alderman</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of the angiotensin-converting enzyme inhibitors.</article-title>
            <source>Ann Pharmacother</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-61</page-range>
            <pub-id pub-id-type="pmid">8773167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmquist</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Isolated intestinal type angioedema due to ACE-inhibitor therapy.</article-title>
            <source>Clin Case Rep</source>
            <year>2017</year>
            <month>May</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>707</fpage>
            <page-range>707-710</page-range>
            <pub-id pub-id-type="pmid">28469880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bharate</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.</article-title>
            <source>J Med Chem</source>
            <year>2021</year>
            <month>Mar</month>
            <day>25</day>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>2923</fpage>
            <page-range>2923-2936</page-range>
            <pub-id pub-id-type="pmid">33706513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hubers</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Mar</month>
            <day>15</day>
            <volume>133</volume>
            <issue>11</issue>
            <fpage>1115</fpage>
            <page-range>1115-24</page-range>
            <pub-id pub-id-type="pmid">26976916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnett</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Buroker</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Himmelfarb</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McEvoy</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Michos</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Miedema</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ziaeian</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular&#x000a0;Disease: A Report of the American College of Cardiology/American Heart Association Task&#x000a0;Force&#x000a0;on&#x000a0;Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Sep</month>
            <day>10</day>
            <volume>74</volume>
            <issue>10</issue>
            <fpage>e177</fpage>
            <page-range>e177-e232</page-range>
            <pub-id pub-id-type="pmid">30894318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stubblefield</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Storrow</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Spertus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Char</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Diercks</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Fermann</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hiestand</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lindenfeld</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>McNaughton</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Schrock</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Self</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department.</article-title>
            <source>Circ Cardiovasc Qual Outcomes</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>e007956</fpage>
            <pub-id pub-id-type="pmid">34555929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Christie</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Waring</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Rapid onset of haemodynamic effects after angiotensin converting enzyme-inhibitor overdose: implications for initial patient triage.</article-title>
            <source>Emerg Med J</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>854</fpage>
            <page-range>854-7</page-range>
            <pub-id pub-id-type="pmid">17057137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-712.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Reet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dens</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Auto-intoxication with flecainide and quinapril: ECG-changes, symptoms and treatment.</article-title>
            <source>Acta Cardiol</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>669</fpage>
            <page-range>669-72</page-range>
            <pub-id pub-id-type="pmid">17205927</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
